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Abstract 
Therapeutic implications of intra-tumor heterogeneity are still undefined. In this study we report a genetic and 
functional analysis aimed at defining the mechanisms of chemoresistance in a 43-year old woman affected by stage 
IVB Burkitt lymphoma with bulky abdominal masses and peritoneal effusion. The patient, despite a transient initial 
response to chemotherapy with reduction of the bulky masses, rapidly progressed and died of her disease. Targeted 
TP53 sequencing found that the bulky mass was wild-type whereas peritoneal fluid cells harbored a R282W muta-
tion. Functional studies on TP53 mutant cells demonstrated an impaired p53-mediated response, resistance to ex vivo 
doxorubicin administration, overexpression of DNA damage response (DDR) activation markers and high sensitivity to 
pharmacologic DDR inhibition. These findings suggest that intra-tumor heterogeneity for TP53 mutational status may 
occur in MYC-driven cancers, and that DDR inhibitors could be effective in targeting hidden TP53 mutant clones in 
tumors characterized by genomic instability and prone to intra-tumor heterogeneity.
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Background
Genomic instability, defined as the tendency to acquire 
DNA damage determining accumulation of genomic 
alterations over time, is a hallmark of cancer conferring 
evolutionary advantages, and resulting in resistance to 
chemotherapy and increased metastatic potential [1]. A 
common mechanism determining genomic instability 
in tumors is oncogene-induced replication stress, lead-
ing to DNA damage accumulation during the S phase of 
the cell cycle [2]. Our group and others recently reported 
that MYC-driven cancers such as Burkitt lymphoma 
(BL) and Diffuse large B-cell lymphoma (DLBCL) over-
express active components of the DNA damage response 
pathway (DDR) such as checkpoint kinases (CHK1/2), 
in order to cope with the high levels of replication stress 
deriving from MYC overexpression, and are sensitive to 
pharmacologic DDR inhibition [3–5]. BL is characterized 
by a high level of MYC expression due to the occurrence 
of chromosomal translocations which are hallmarks of 
the disease, and G1/S checkpoint dysfunction with fre-
quent TP53 mutations (30 % of cases) [6, 7]. TP53 muta-
tions drive chemoresistance in many different cancers 
including aggressive B-cell lymphomas [8, 9], and coop-
erate with MYC by preventing its intrinsic proapoptotic 
effects and by further increasing genomic instability [10]. 
Intra-tumor heterogeneity, intended as the occurrence 
of genomic diversities within the same tumor over space 
and time, is intimately related to genomic instability, and 
has been recently unraveled by next generation sequenc-
ing (NGS) studies [11]. Nevertheless, its clinical signifi-
cance and therapeutic implications in aggressive B-cell 
lymphomas are yet to be elucidated.
In the current study we report a genetic and func-
tional analysis aimed at defining the mechanisms of 
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chemoresistance in a 43-year old woman affected by stage 
IVB Burkitt lymphoma with bulky abdominal masses and 
peritoneal effusion. The patient, despite a transient initial 
response to chemotherapy with reduction of the bulky 
masses, rapidly progressed and died of her disease. Tar-
geted TP53 sequencing found that the bulky mass was 
wild-type (WT) whereas peritoneal fluid cells harbored 
a R282W mutation, depicting a paradigmatic example 
of intra-tumor heterogeneity for the TP53 mutational 
status at disease onset in BL. Functional studies on the 
TP53 mutant clone confirmed an impaired p53-mediated 
response and resistance to ex  vivo doxorubicin admin-
istration. Finally, we demonstrated that these cells were 
characterized by overexpression of markers of genomic 
instability and DDR pathway activation, and were sensi-
tive to pharmacologic inhibition of CHK kinases.
Case presentation
The patient was hospitalized in August 2011 in critical con-
ditions with two bulky abdominal masses originating from 
both ovaries, a massive abdominal effusion and small bowel 
obstruction. Surgical biopsy of the bulky mass (left ovary), 
cytology of the malignant cells from ascitic fluid, and 
immunophenotype (CD20+, CD19+, CD10+, BCL6+, 
CD38+, c-MYC) led to the diagnosis of BL (Fig.  1a–d). 
Fluorescence in  situ hybridization (FISH) on malignant 
cells from both bulky mass and ascitic fluid showed a 
t(8;22)(q24;q11) translocation involving the MYC oncogene 
and the lambda light chain locus (IGL) (Fig. 1e). Detailed 
description of Immunohistochemistry and FISH studies is 
available in Additional file 1. The principal comorbidity was 
a severe bipolar disorder and anorexia nervosa that was still 
active at the time of disease onset, so that the patient was 
severely underweight (body mass index <17  kg/m2) and 
deemed initially unfit for intensive chemotherapy. Initial 
treatment consisted in 5 days of debulking cyclophospha-
mide (200 mg/m2/die) followed by 1 CHOP (cyclophospha-
mide, doxorubicin, vincristine, prednisone) cycle, which 
was complicated by severe tumor lysis syndrome, and 
bowel perforation requiring surgical intervention (Fig. 1f–
i). A computed tomography (CT) scan performed after the 
first cycle showed marked reduction of the bulky lesions, 
with persistence of the abdominal effusion (Fig. 1g). After 
recovering from surgery, she received two additional Ritux-
imab-CHOP-14 cycles but a CT scan performed right after 
showed marked disease progression (Fig. 1h). At this point 
the patient underwent therapy intensification according to 
the B-NHL-2002 regimen [12] but was unresponsive and 
ultimately died of rapidly progressing disease. Since recent 
studies confirmed that TP53 mutations occur in about 30 % 
of BL cases [6, 7], in order to investigate the mechanisms 
underlying resistance to standard and intensive chemo-
therapy in this patient, we performed TP53 targeted DNA 
sequencing of the tumor tissue available from the initial 
biopsy (left ovary), of tumor cells initially collected from 
the ascitic fluid, and of matched normal saliva using the 
454 GS Junior platform (Roche diagnostics) (Additional 
file  1). The patient gave informed consent for the use of 
surplus tissue in research, and the protocol was approved 
by the Institutional Review Board (Study n 12/2009/U/
Tess, protocol 148/2009). We found that the tumor tissue 
from the initial bulky mass was entirely TP53 wild type, 
whereas lymphoma cells from the abdominal effusion har-
bored an heterozygous R282W mutation (Fig. 1j, k), which 
resulted in a 844C>T aminoacidic change, known to nega-
tively affect p53 function and being associated to shorter 
survival in different cancer models (IARC database http://
p53.iarc.fr/TP53GeneVariations.aspx) [13, 14]. These find-
ings were confirmed by Sanger sequencing (Fig. 1l). Nota-
bly, both samples were chemonaive being collected before 
the start of chemotherapy. In order to define the impact of 
the R282W mutation on response to therapy in this specific 
case, we treated cultured TP53 mutant primary BL cells 
from the ascitic fluid with either DMSO 0.01 % or doxoru-
bicin 500 nM (Fig. 2a). The TP53 wild type Hodgkin lym-
phoma cell line KM-H2 was used as a control. According to 
the TP53 status, primary mutant BL cells were resistant to 
doxorubicin, whereas KM-H2 cells were sensitive. Consist-
ent with these data, doxorubicin induced p21 expression in 
KM-H2 cells but not in primary BL cells (Fig. 2b). Interest-
ingly, as shown in Fig. 1, while the TP53 WT bulky masses 
rapidly responded to chemotherapy, the malignant TP53 
mutant ascites was still present at the time of second CT 
scan despite multiple repeated paracenteses (Fig. 1g), indi-
cating a similar chemoresistant behavior also in vivo. Cell 
viability assays were performed by using WST-1 reagent 
(Roche). Detailed description of western blot protocols, 
antibodies and reagents is available in Additional file 1. 
Since we recently reported constitutive DDR activa-
tion and high efficacy of CHK inhibitors in TP53 mutant 
aggressive B-cell lymphomas (DLBCL and BL) [5], we 
evaluated the expression levels of genomic instability 
and DDR activation markers [5, 15] in peritoneal fluid 
cells and in the bulky mass by western blotting (Fig. 2c) 
and immunohistochemistry (Fig.  2d–i) confirming that 
peritoneal fluid cells demonstrated constitutive γH2AX 
(H2AX S139) and p-CHK1 S345 expression (Fig.  2c–e). 
Notably, although to a lesser extent, we observed posi-
tivity for these markers also in the TP53 WT bulky mass 
(Fig.  2f, g), suggesting that the acquisition of genomic 
instability and of a DDR+ phenotype was an intrinsic fea-
ture of this neoplasm that preceded the development of 
the TP53 mutation. The TP53 WT KM-H2 cells, used as 
negative control of DDR activation [5], were negative for 
both p-CHK1 and γH2AX (Fig. 2h, i). Next, in order to 
assess whether the TP53 mutant subclone was sensitive 
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Fig. 1 Clinical history, therapeutic interventions and TP53 sequencing results. a–d Immunohistochemistry slides showing Burkitt lymphoma 
medium-sized cells (Giemsa stain) expressing CD20 (b) and CD10 (c) (×400); c-MYC positivity in the inset (c). Peritoneal fluid collected at the 
moment of initial diagnosis (d), showing monomorphic BL cells with frequent mitotic figures. e FISH analysis of cells from peritoneal fluid using the 
Whole Chromosome Painting (WCP) probes of chromosomes 8 and 22, respectively pseudo-colored in red and green. The results showed the occur-
rence of the recurrent t(8;22)(q24;q11) translocation. f–i Clinical course of the patient depicted over a 4 months period with time points of CT scans 
performed at initial diagnosis (f), after a first chemotherapy cycle (g), and at disease progression (h), and different therapeutic interventions (i). j, k 
TP53 deep targeted sequencing study of cells from the bulky mass and peritoneal fluid, showing the presence of R282W mutation in the peritoneal 
(ascitic) fluid cells but not in the bulky mass. l Sanger sequencing analysis confirming the presence of a heterozygous R282W mutation in the cells 
from peritoneal fluid, and lack of mutation in the bulky mass.
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to DDR inhibition, we treated primary ascitic fluid BL 
cells (DDR+) and KM-H2 cells (DDR-) with the CHK 
inhibitor PF-0477736, finding that peritoneal fluid cells 
were exquisitely sensitive to CHK inhibition whereas 
KM-H2 cells were resistant (Fig. 2j). Following CHK inhi-
bition, γH2AX levels increased in primary peritoneal 
Fig. 2 Functional ex vivo studies showing doxorubicin resistance and sensitivity to DDR inhibition in TP53 mutant cells from peritoneal effusion. a 
WST-1 viability assay of primary ascitic fluid BL cells and KM-H2 cells treated with DMSO and doxorubicin 500 nM for 24 h. The percentage of viable 
cells after treatment in each cell line was normalized to its own untreated (DMSO) control. b Western blot analysis of BL TP53 mutant primary cells 
and TP53 wild type HL-derived KM-H2 cells showing p21 induction in KM-H2 cells after doxorubicin (doxo) treatment (500 nM for 6 and 24 h). c 
Western blot analysis of BL TP53 mutant primary cells and TP53 wild type HL-derived KM-H2 cells showing relative overexpression of pCHK1 S345 
and pH2AX S139 in primary BL TP53 mutant BL cells, compared to TP53 wild type KM-H2 cells. d–i Immunocytochemistry for p-CHK1 S345, p-H2AX 
S139, in cultured primary cells from peritoneal fluid (d, e), the bulky mass (f, g), and KM-H2 cells (g, h) confirming western blot findings (×400). j 
WST-1 viability assay of primary BL cells from ascitic fluid and KM-H2 cells treated with DMSO and PF-0477736 250 nM for 24 h. The percentage of 
viable cells after treatment in each cell line was normalized to its own untreated (DMSO) control. k Western blot assay of TP53 mutant primary BL 
cells from ascitic fluid and TP53 wild type HL-derived KM-H2 cells showing pH2AX S139 induction in primary BL cells after PF-0477736 treatment 
(250 nM for 24 h).
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fluid cells, indicating that in these cells the blockade of 
DDR leads to accumulation of endogenous DNA damage 
(Fig.  2k). These findings are consistent with a model in 
which constitutive activation of CHK kinases cooperates 
with MYC and is crucial to prevent untolerable levels of 
genomic instability deriving from MYC-induced replica-
tion stress and G1/S checkpoint dysfunction.
Conclusions
These observations could have broad implications in 
clinical practice, suggesting that multiple tumor sam-
ples from different regions should be evaluated before 
tailoring therapies based on genome sequencing results. 
Although no definitive conclusions can be drawn from 
single case studies, this report strongly corroborates pre-
vious findings from our group and others showing effi-
cacy of CHK inhibitors in MYC-driven and TP53 mutant 
lymphoma models, suggesting that: (1) the occurrence of 
clonal heterogeneity at disease onset for mutations driv-
ing chemoresistance, such as those in TP53, should be 
taken into account in aggressive MYC-driven lympho-
mas; (2) CHK inhibitors could be effective in targeting 
hidden TP53 mutant clones in tumors characterized by 
genomic instability and prone to intra-tumor heteroge-
neity. In conclusion, these data indicate that multiregion 
sequencing will be a crucial step for the development of 
precision therapy in aggressive B-cell lymphomas and 
confirm that inhibition of CHK kinases could be a suit-
able therapeutic strategy for MYC-driven tumors, which 
should be evaluated in future clinical trials.
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